Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.


s of the 46th Annual ICAAC; September 27–30,<lb>2006; San Francisco, CA. Poster A-0374.<lb>8. Kumar PN CD, Steigbigel RT, et al. Efficacy of raltegravir, an<lb>integrase inhibitor, in combination with regimens containing<lb>enfuvitide, darunavir, or tipranavir in patients with tripleclass resistant virus: combined results from BENCHMRK-1<lb>and BENCHMRK-2… (More)
DOI: 10.1310/hct0902-140


1 Figure or Table